TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06187012

Intervention type: OTHER
Intervention: Hypertensive pregnancy
Description: Participants will attend one visit lasting approximately 3-4 hours on a single day or split over multiple visits to complete all measures. Participants will first be asked to provide written informed consent for the study. Participants' anthropometric measures (waist-to-hip ratio, height and weight, hip and waist circumference and left arm circumference and resting blood pressures will then be taken. After this, the participants will undergo cardiopulmonary exercise testing, followed by magnetic resonance imaging, echocardiography, retinal imaging and vascular imaging of the ear. The study visit will conclude with participants being provided with a wrist-worn physical activity monitor to wear for 7-9 days following the visit. These monitors will provide objective measures of physical activity while people go about their normal activities.
Study: NCT03569514

Intervention type: DRUG
Intervention: AIGIV
Description: Anthrax Immune Globulin Intravenous (Human)
Study: NCT06308614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg estetrol monohydrate
Description: Active treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to E4
Study: NCT06202378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 ampoules of SHPL-49 Injection
Description: 3 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 ampoules of SHPL-49 Injection
Description: 6 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
Study: NCT06065631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyeglasses
Description: Children with uncorrected/under-corrected refractive error will be provided with either ready made or custom eyeglasses based on their magnitude and types of refractive errors.

Intervention type: OTHER
Group type: OTHER
Intervention: Prescription slip
Description: Children with uncorrected/under-corrected refractive error will be provided with an eyeglasses prescription and letter to parents, but all of them will get eyeglasses at the end of the trial
Study: NCT05427370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularization by PCI
Description: Contemporary, State-of-the-art PCI techniques will be encouraged in STICH3C, based on the most recent evidence and clinical practice guidelines recommendations. The best practices to be followed include the use of physiological and intravascular guidance, new-generation drug-eluting stents or scaffolds, rotational or orbital atherectomy for extensive calcifications, recommended bifurcation techniques, chronic total occlusion for viable segments by experienced operators, and trans-radial access.Planned temporary ventricular support is permitted by experienced operators when deemed indicated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularization by CABG
Description: The surgical revascularization strategy will be tailored according to the individual patient's coronary anatomy, left ventricular remodeling, aortic atherosclerosis, co-morbidities, local expertise, and surgical judgement. An internal thoracic artery will be used to graft the left anterior descending in all cases. Multi-arterial grafting may be considered in patients without significant co-morbidities and with expected limited vasopressor use, or in patients without saphenous conduits. Choice of on- vs. off-pump surgery is influenced by LV size, associated valvular disease, and aortic atherosclerosis, as well as surgeon experience, but on-pump surgery is recommended routinely. The use of adjunctive intra-aortic balloon support or other cardiac support is not routinely recommended in stable patients; the intra-aortic balloon support is the first line mechanical support.
Study: NCT06568705

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Moderate hypofractionated Radiation Treatment
Description: The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 43.5Gy in 15 fractions in patients who underwent breast conserving surgery or mastectomy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrafractionated Radiation Treatment
Description: The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 26Gy in 5 fractions in patients who underwent breast conserving surgery or mastectomy.
Study: NCT06578234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Standard dose 140 μg/kg/min and high dose 210 μg/kg/min adenosine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Standard dose 140 μg/kg/min and high dose 210 μg/kg/min adenosine
Study: NCT05033288

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality of life questionnaires
Study: NCT04840355

Intervention type: DRUG
Intervention: Sintilimab Injection
Description: The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Intervention: Sintilimab Injection
Description: The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Intervention: Sintilimab Injection
Description: The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.
Study: NCT05725876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Patients not on therapy and patients on therapy will undergo fluorescence molecular imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Patients not on therapy and patients on therapy will undergo fluorescence molecular imaging.
Study: NCT06634966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Description: The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
Study: NCT05844293

Intervention type: DRUG
Group type: OTHER
Intervention: FXI-GalNAc-siRNA
Description: FXI-GalNAc-siRNA solution for injection

Intervention type: DRUG
Group type: OTHER
Intervention: FXI-GalNAc-siRNA
Description: FXI-GalNAc-siRNA solution for injection
Study: NCT06635161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trancranial pulse stimulation (without a stand-off device)
Description: A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). No stand-off device will be used to target dorsal anteior cingulate cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial pulse stimulation (with Neurology stand-off device)
Description: A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A Neurology stand-off device will be used to target the anterior insula cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial pulse stimulation (with a sham stand-off device)
Description: A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A sham stand-off device will be used to target vertex.
Study: NCT05844293

Intervention type: DRUG
Group type: OTHER
Intervention: FXI-GalNAc-siRNA
Description: FXI-GalNAc-siRNA solution for injection

Intervention type: DRUG
Group type: OTHER
Intervention: FXI-GalNAc-siRNA
Description: FXI-GalNAc-siRNA solution for injection

Intervention type: DRUG
Group type: OTHER
Intervention: FXI-GalNAc-siRNA
Description: FXI-GalNAc-siRNA solution for injection

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Saline
Study: NCT06362538

Intervention type: OTHER
Group type: OTHER
Intervention: International Physical Activity Questionnaire
Description: Assessments of physical activity level and functional capabilities (aerobic capacity, muscular strength and power, flexibility

Intervention type: OTHER
Group type: OTHER
Intervention: Six minute walking test
Description: The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

Intervention type: OTHER
Group type: OTHER
Intervention: SF-36, Euro-Qol 5D-5L, Perceived stress scale-10, Pittsburgh Sleep Quality Index, Depression Anxiety Stress scale- 21.
Description: Evaluation of the quality of life, the psychological sphere (anxiety, stress, depression) and the quality of sleep
Study: NCT06285812

Intervention type: DEVICE
Intervention: OtoSight Middle Ear Scope
Description: Subjects will be evaluated with the OtoSight Middle Ear Scope

Intervention type: DEVICE
Intervention: OtoSight Middle Ear Scope
Description: Subjects will be evaluated with the OtoSight Middle Ear Scope
Study: NCT06362538

Intervention type: OTHER
Group type: OTHER
Intervention: MEDAS
Description: Evaluation of adherence to the Mediterranean diet

Intervention type: OTHER
Group type: OTHER
Intervention: Intima-media thickness (IMT)
Description: Bmode ultrasonography

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Measurement of parameters for defining cardiovascular risk and biomarkers.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stool Sample Culture Test
Description: Evaluation of Gut Microbiota
Study: NCT06123169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibioprophylaxis (Piperacillin-tazobactam)
Description: antibiotic prophylaxis during surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 days Antibiotherapy (Piperacillin-tazobactam)
Description: 5 days Antibiotherapy from surgery
Study: NCT06210113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: An 8-week Mindfulness-based stress reduction training programme
Study: NCT06041360

Intervention type: DIAGNOSTIC_TEST
Intervention: Pure tone audiometry PTA ,Speech audiometry ,Otoacoustic emission,Auditory evoked potentials including (ABR).
Description: Neurological tests for diagnosis of peripheral neuropathy

Intervention type: DIAGNOSTIC_TEST
Intervention: Pure tone audiometry PTA ,Speech audiometry ,Otoacoustic emission,Auditory evoked potentials including (ABR).
Description: Neurological tests for diagnosis of peripheral neuropathy
Study: NCT06418022

Intervention type: DEVICE
Group type: OTHER
Intervention: Trendelenburg positioning VTI
Description: There are essentially two arms, whereby the patients is being compared to themselves. The intervention arm is the same patient undergoing TP from the baseline supine position to determine the change in VTI after subjecting to TP.~We will be using a Sonosite PX ultrasound system, which is intended for diagnostic ultrasound imaging or fluid flow analysis of the human body and, more specifically, for our echocardiographic measurements of velocity time integral (VTI; surrogate for stroke volume and cardiac output). The Sonosite PX is a general-purpose ultrasound system intended for use by qualified physicians and healthcare professionals, for evaluation by ultrasound imaging or fluid flow analysis of the human body. This is an FDA-cleared (510K# K200964) commercial device legally marketed in the United States that is being used in accordance with labeling.
Study: NCT06089564

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skit video, Pictorial, Sign language
Description: Three oral health educational intervention groups, group A (skit video), group B (pictorial) and group C (sign language) by using Sequentially Numbered Sealed Opaque Envelopes (SNOSE). Children picked a sealed envelope randomly and assigned to oral health education intervention group A, B and C. Participants in group A were assigned a skit video method of oral hygiene intervention and shown 5 minute video on what to eat and how to brush their teeth. The video included that what is good and bad for teeth, and how to brush which includes method, time and duration of tooth brushing. Participants assigned to group B and C was provided same instructions for tooth brushing and eating habits in the form of pictures and sign language respectively. The children of Group A received instructions in the form of laminated cards and asked to take with them at home. Participants in group C were received instructions in sign language in the presence of teacher.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skit video, Pictorial, Sign language
Description: Three oral health educational intervention groups, group A (skit video), group B (pictorial) and group C (sign language) by using Sequentially Numbered Sealed Opaque Envelopes (SNOSE). Children picked a sealed envelope randomly and assigned to oral health education intervention group A, B and C. Participants in group A were assigned a skit video method of oral hygiene intervention and shown 5 minute video on what to eat and how to brush their teeth. The video included that what is good and bad for teeth, and how to brush which includes method, time and duration of tooth brushing. Participants assigned to group B and C was provided same instructions for tooth brushing and eating habits in the form of pictures and sign language respectively. The children of Group A received instructions in the form of laminated cards and asked to take with them at home. Participants in group C were received instructions in sign language in the presence of teacher.
Study: NCT06022432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video of a patients testimonial
Description: The intervention is a prerecorded video of a re-enacted patient-therapist interaction whereby the patient gives a testimonial about the treatment process while either reducing negative expectations or maximizing positive expectations about therapy, respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video of a patients testimonial
Description: The intervention is a prerecorded video of a re-enacted patient-therapist interaction whereby the patient gives a testimonial about the treatment process while either reducing negative expectations or maximizing positive expectations about therapy, respectively.

Intervention type: OTHER
Group type: OTHER
Intervention: Writing Task
Description: Participants write freely about their current treatment expectations / apprehensions to seek treatment
Study: NCT06311916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC + Tirelizumab +lenvatinib +liver resection
Description: Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days) + Tirelizumab (First treatment with Tirelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)+ lenvatinib (Oral 8 mg or 12mg once a day depending body weight). Assessment of tumor status and surgical safety after receiving neoadjuvant therapy, and eligible patients then underwent surgical resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver resection
Description: Direct liver resection or laparoscopic liver resection depending on tumor status.
Study: NCT06534593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar Traction
Description: Lumbar traction using traction table

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mckenzie Extension Protocol
Description: Mckenzie Extension Exercises

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential Therapy
Description: Interferential Therapy for 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat Therapy
Description: Heat Therapy for 20 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained Natural Apophyseal Glides (SNAGs)
Description: 3-5 reptations of Mulligan's lumbar extension Sustained Natural Apophyseal Glides (SNAGs)
Study: NCT05760196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: PD1 antibody is held every three weeks, and GM-CSF is used once every three weeks on days 1-14. Until the patient progresses disease or intolerable toxicity.
Study: NCT05779683

Intervention type: DEVICE
Intervention: Caretaker Device placement
Description: placement of the device on the postoperative cardiac surgery patient that has a pulmonary artery catheter for comparison readings
Study: NCT05666635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LTC004
Description: LTC004 Phase I:Participants will be allocated to one of the following dose groups: 3, 15, 45, 90, 180，270,360 and 450 ug/kg, and receive a treatment of LTC004 followed by 21 days of dose limited toxicity (DLT) observation period.~Phase Ib indication exploration~Other Name: LTC004 for Injection
Study: NCT06383754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon
Description: Monofocal intraocular lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis 1
Description: Monofocal 1 Piece intraocular lens
Study: NCT05484622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Description: Administered orally as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Description: Administered orally as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Description: Administered orally as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as IV infusion.
Study: NCT05794243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Caprate (C10)
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Caprate (C10)
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salcaprozate Sodium (SNAC)
Description: Administered orally.
Study: NCT05422040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Invasive treatment will be performed on the most symptomatic lumbar iliocostalis muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tecartherapy treatment
Description: Treatment will be carried out with deep thermotherapy in the lumbar region.
Study: NCT05112172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
Study: NCT04479176

Intervention type: PROCEDURE
Intervention: Transnasal Sphenopalatine Ganglion Block
Description: In transnasal approach, several authors described the traditional technique using sterile 10cm cotton tipped applicators that are dipped in the chosen anesthetic and then advanced along the superior border of the middle turbinate, until it reaches the posterior wall of the nasopharynx. Some other techniques had described dripping one or two ml of the anesthetics into the nostril.

Intervention type: PROCEDURE
Intervention: Transnasal Sphenopalatine Ganglion Block
Description: In transnasal approach, several authors described the traditional technique using sterile 10cm cotton tipped applicators that are dipped in the chosen anesthetic and then advanced along the superior border of the middle turbinate, until it reaches the posterior wall of the nasopharynx. Some other techniques had described dripping one or two ml of the anesthetics into the nostril.
Study: NCT05331131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Topical
Description: Ketamine hydrochloride in mouthwash form
Study: NCT06193356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning tool
Description: Video based learning tool about detection of endoscopic resection scars and recurrence.
Study: NCT05466123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Simulated travel destination or activity of the participants choosing that would otherwise be inaccessible
Study: NCT06367621

Intervention type: DEVICE
Intervention: iStatis Syphilis Antibody Test
Description: 1500 stored samples (plasma/serum) will be tested in a routine testing environment using the iStatis Syphilis Antibody Test diagnostic device. Results of tests will not be used for patient management decisions (observaltional).
Study: NCT05222932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TILT-123
Description: TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PDL1 antibody
Study: NCT05147415

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tesomet
Description: Fixed-dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesomet
Description: Fixed-dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesomet
Description: Fixed-dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesomet
Description: Fixed-dose combination